For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives ...
Immunis Inc. has struck a licensing deal with Japanese material manufacturer Toray Industries Inc. to develop a potential ...
India, March 18 -- Stem cell therapies using induced pluripotent stem cells have received conditional approval in Japan for ...
Research from FIU scientists have discovered a promising new compound that could slow the progression of Parkinson's disease ...
L-leucine, an FDA-approved compound, exerts neuroprotective effects in Parkinson’s disease models. By reducing ...
Since 2008, Labroots has used its virtual events to connect a global network of scientists regarding the latest advancements ...
Aspen's sasineprocel is an autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) ...
VALBY, Denmark - H. Lundbeck A/S announced today that phase 1b trial data for Lu AF28996, an investigational treatment for advanced Parkinson’s disease, will be presented at the 2026 Alzheimer’s and ...
Known early on for skin-baring temptress roles, she later earned rave reviews, a Cannes award and an Oscar nomination for her ...
GOTHENBURG, SE / ACCESS Newswire / March 17, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that i ...
Sasineprocel’s encouraging Phase I/IIa data positions autologous iPSC-derived dopaminergic neuron therapy as a potential monotherapy challenger in Parkinson’s disease (PD), signaling a shift toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results